ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Protection with Issuance of 10th and 11th Chinese Patents
March 30 2022 - 9:12AM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer
of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the
Chinese National Intellectual Property Administration has issued
ENDRA two new patents, Chinese Patent No. ZL 2019 8 00400927 (the
‘927 patent) titled “Method and System for Determining Fractional
Fat Content of Tissue,” and Chinese Patent No. ZL 2019 8 00870250
(the ‘250 patent) titled “Radio Frequency Applicator and
Thermoacoustic Imaging System Employing the Same”.
“Having recently announced our first research partnership in
China with the renowned Shanghai General Hospital, we are keen to
bolster our intellectual property protection in Asia’s largest
healthcare market. We now have 11 patents issued in China
supporting our strategy to develop thermoacoustic imaging systems
and broadening the application for our proprietary TAEUS technology
in areas with unmet clinical needs," stated ENDRA's Chairman and
Chief Executive Officer Francois Michelon. "We continue to enhance
our intellectual property portfolio to protect our technology in
priority global markets. Our portfolio currently stands at 89
assets, which we define as patents issued, filed or in
preparation.”
The ‘927 patent covers a method and system for determining
fractional fat content of tissue that takes into consideration the
speed of sound in that tissue. This patent builds upon ENDRA's
growing number of issued patents in the area of tissue fat
quantification. Conventional ultrasound image formation
methodologies assume a single speed of sound, while the ‘927 patent
leverages TAEUS' inherent sensitivity to fractional fat differences
in tissue to estimate the actual speed of sound in tissue, and
thereby improves the accuracy of TAEUS fat quantification
methodologies. The patent also describes a calibration methodology
for fractional fat measurements. The ‘927 patent is linked to its
parent, U.S. patent No. 10258277B2.
The ‘250 patent provides more robust intellectual property
protection for the TAEUS platform related to its disruptive
scanning approach. It covers a radio frequency (RF) applicator
device and system for providing reliable RF energy to a target area
of tissue. More specifically, the '250 patent structurally defines
ENDRA's innovative solution to providing targeted RF energy to
tissue regions for applications, such as fat quantification of a
patient's liver. The ‘250 patent is linked to its parent, U.S.
patent No. 10682059B1.
About ENDRA Life Sciences
Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
400,000 cart-based ultrasound systems in use globally today. TAEUS®
is initially focused on the measurement of fat in the liver as a
means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and inflammation (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
Forward-Looking
Statements
All statements in this news release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” "anticipate," “attempt,” "believe,"
"could," "estimate," "expect," “future,” "goal," "intend," "may,"
"plan," “possible,” “potential,” "seek," "should," "will," or other
comparable terms (including the negative of any of the foregoing),
although some forward-looking statements are expressed differently.
Examples of forward-looking statements for ENDRA include, among
others, estimates of the timing of future events and anticipated
results of our development efforts, including the timing for
receipt of required regulatory approvals and product launches,
expectations concerning ENDRA's business strategy, ENDRA’s ability
to find and maintain development partners, market acceptance of its
technology and the amount and nature of competition in its
industry, and its ability to protect its intellectual property.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others, ENDRA’s ability to develop a commercially
feasible technology and its dependence on third parties to design
and manufacture its products; receipt of necessary regulatory
approvals; the impact of COVID-19 on ENDRA’s business plans;
ENDRA’s ability to find and maintain development partners, market
acceptance of ENDRA’s technology and the amount and nature of
competition in its industry; ENDRA’s ability to protect its
intellectual property; and the other risks and uncertainties
described in the Risk Factors and Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of the Company’s most recent Annual Report on Form 10-K and in
subsequently filed Quarterly Reports on Form 10-Q filed with the
Securities and Exchange Commission. You should not rely upon
forward-looking statements as predictions of future events. The
forward-looking statements made in this news release speak only as
of the date of issuance, and ENDRA assumes no obligation to update
any such forward-looking statements to reflect actual results or
changes in expectations, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220330005566/en/
Company: Irina Pestrikova Senior Director, Finance
investors@endrainc.com www.endrainc.com Investor Relations:
Yvonne Briggs LHA Investor Relations (310) 691-7100
YBriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024